Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial

BACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for preven...

Descripción completa

Detalles Bibliográficos
Autores principales: Eikelboom, John W, Jolly, Sanjit S, Belley-Cote, Emilie P, Whitlock, Richard P, Rangarajan, Sumathy, Xu, Lizhen, Heenan, Laura, Bangdiwala, Shrikant I, Luz Diaz, Maria, Diaz, Rafael, Yusufali, Afzalhussein, Kumar Sharma, Sanjib, Tarhuni, Wadea M, Hassany, Mohamed, Avezum, Alvaro, Harper, William, Wasserman, Sean, Almas, Aysha, Drapkina, Oxana, Felix, Camilo, Lopes, Renato D, Berwanger, Otavio, Lopez-Jaramillo, Patricio, Anand, Sonia S, Bosch, Jackie, Choudhri, Shurjeel, Farkouh, Michael E, Loeb, Mark, Yusuf, Salim
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635892/
https://www.ncbi.nlm.nih.gov/pubmed/36228641
http://dx.doi.org/10.1016/S2213-2600(22)00298-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9635892/
https://www.ncbi.nlm.nih.gov/pubmed/36228641
http://dx.doi.org/10.1016/S2213-2600(22)00298-3

Ejemplares similares